Journal article 319 views 50 downloads
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
,
Sarah Davies,
Debbie Hicks,
Pam Brown,
Zaheer Yousef,
Umesh Dashora,
Adie Viljoen,
Hannah Beba,
W. David Strain
Diabetes Therapy, Volume: 13, Issue: 2, Pages: 225 - 240
Swansea University Author:
Steve Bain
-
PDF | Version of Record
©The Author(s) 2022. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License
Download (763.8KB)
DOI (Published version): 10.1007/s13300-021-01201-z
Abstract
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. Howev...
| Published in: | Diabetes Therapy |
|---|---|
| ISSN: | 1869-6953 1869-6961 |
| Published: |
Springer Science and Business Media LLC
2022
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa59059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. However, an oral formulation of semaglutide was recently licensed, with the potential to address therapy inertia and increase patient adherence to treatment, which is essential in controlling blood glucose and reducing complications. The availability of oral semaglutide provides a new option for both clinicians and patients who are reluctant to use an injectable agent. This has been of particular importance in addressing the challenge of virtual diabetes care during the COVID-19 pandemic, circumventing the logistical problems that are often associated with subcutaneous medication administration. However, there remains limited awareness of the clinical and economic value of oral semaglutide in routine clinical practice. In this article, we present our consensus opinion on the role of oral semaglutide in routine clinical practice and discuss its value in reducing the burden of delivering diabetes care in the post-COVID-19 pandemic period of chronic disease management. |
|---|---|
| Keywords: |
Glucagon-like peptide-1 receptor agonists; Oral semaglutide; Type 2 diabetes |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
2 |
| Start Page: |
225 |
| End Page: |
240 |